Market Overview - The Shanghai Composite Index rose by 1.14% on August 28, with 22 out of 28 sectors experiencing gains, led by the communication and electronics sectors, which increased by 7.14% and 5.53% respectively [1] - Conversely, the coal and agriculture sectors saw declines of 0.81% and 0.73% respectively, while the pharmaceutical and biotechnology sector fell by 0.20% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 44.343 billion yuan, with five sectors experiencing net inflows. The electronics sector led with a net inflow of 10.553 billion yuan, followed by the communication sector with 4.998 billion yuan [1] - In contrast, 26 sectors faced net capital outflows, with the computer sector experiencing the largest outflow of 11.007 billion yuan, followed by the pharmaceutical and biotechnology sector with an outflow of 7.892 billion yuan [1] Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector had a net outflow of 7.892 billion yuan, with 474 stocks in the sector. Out of these, 121 stocks rose, including 2 that hit the daily limit, while 346 stocks declined [2] - Notably, the top three stocks with the highest net inflow were Tibet Pharmaceutical with 320 million yuan, followed by Furuide with 293 million yuan, and Jimin Health with 126 million yuan [2] - The sector's outflow was dominated by WuXi AppTec, which saw a net outflow of 596 million yuan, followed by Borui Pharmaceutical and Hanyu Pharmaceutical with outflows of 548 million yuan and 339 million yuan respectively [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●公司股票交易于2025年8月27日、8月28日连续二个交易日内收盘价格涨幅 偏离值累计超过20%，属于《上海证券交易所交易规则》规定的股票交易异常波动 情形。 ●经公司自查并书面征询控股股东及实际控制人，截至本公告披露日，公司 不存在应披露而未披露的重大事项。 一、股票交易异常波动的具体情况 证券代码：603222 证券简称：济民健康 公告编号：2025-042 济民健康管理股份有限公司 关于股票交易异常波动的公告 ●公司敬请广大投资者注意二级市场交易风险、经营业绩风险，敬请广大投 资者理性决策，审慎投资。 济民健康管理股份有限公司（以下简称"公司"）股票于 2025 年 8 月 27 日、 8 月 28 日连续二个交易日内收盘价格涨幅偏离值累计达到 20%，根据《上海证券 交易所交易规则》的相关规定，属于股票交易异常波动。 二、公司关注并核实的相关情况 针对股票交易异常波动情况，公司对有关事项进行了核查，现将有关情况说 明如下： （一）经公司自查，公司主 ...

关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 本公司持有济民健康管理股份有限公司 24. 37%的股份,为济民健康管理股 份有限公司控股股东。 本公司于 2025 年 8 月 28 日收到你公司发来的《关于济民健康管理股份有 限公司股票交易异常波动的征询函》,现就你公司征询事项回复如下: 一、本公司不涉及你公司的应披露而未披露的重大信息,不存在针对你公司 的重大资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和 资产注入等重大事项。 二、无其他重大事项。 (以下无正文) 此页无正文,为《关于济民健康管理股份有限公司股票交易异常波动的征询函的 回函》之盖章页) -双鸽集团有限公司 2025年8月28日 关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 济民健康管理股份有限公司: 李仙玉: nda dri 张雪琴: 李慧慧: 李丽莎: 田云飞: t 别 涌: 2025 年 8 月 28 日 济民健康管理股份有限公司: 本家族成员直接持有济民健康管理股份公司(以下简称"公司")股份 7,727.70万股,占公司总股本的 14.72%,并持有公司控股股东双鸽集团有限公 司 1 ...

Market Overview - The medical device sector experienced a slight decline of 0.08% on August 28, with Tuo Jing Life leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Top Performers - Fu Rui Co., Ltd. (300049) saw a significant increase of 15.35%, closing at 65.02 with a trading volume of 461,000 shares and a transaction value of 2.915 billion [1] - Ji Min Health (603222) rose by 9.96%, closing at 11.04 with a trading volume of 1.27 million shares [1] - Hua Kang Clean (301235) increased by 6.84%, closing at 34.38 with a trading volume of 64,100 shares [1] Underperformers - Tuo Jing Life (300642) declined by 5.41%, closing at 27.97 with a trading volume of 263,500 shares and a transaction value of 735 million [2] - Xiang Sheng Medical (688358) fell by 4.97%, closing at 32.12 with a trading volume of 37,700 shares [2] - Tian Zhi Hang (688277) decreased by 4.77%, closing at 18.38 with a trading volume of 261,600 shares [2] Capital Flow - The medical device sector saw a net outflow of 1.115 billion from institutional investors, while retail investors contributed a net inflow of 965 million [2][3] - The top net inflows from retail investors were observed in Fu Rui Co., Ltd. (300049) with 30.3 million and Ji Min Health (603222) with 11.5 million [3]

Group 1 - The ChiNext Index rose by 3.82%, and the Sci-Tech 50 Index surged over 7%, indicating a strong performance in the AI technology sector [1] - Tianpu Co., Ltd. achieved a five-day consecutive increase in stock price, reflecting positive market sentiment [1] - Companies like Feile Audio and Tianfu Communication are expanding their product offerings in automotive electronics and high-power semiconductor chips, respectively [3][5] Group 2 - Nvidia's CFO predicts that AI infrastructure spending will reach $3-4 trillion by 2030, highlighting the growing investment in AI technologies [3] - Longfly Optical Fiber, a leading global player in the optical fiber and cable industry, has secured projects with advanced hollow core technology [3] - Companies such as East Mountain Precision and Deep South Circuit are making significant moves in the PCB and electronic materials sectors, with acquisitions and expansions planned [5][6] Group 3 - The State Council has issued guidelines to promote the development of the satellite communication industry, indicating government support for this sector [6] - Companies like Aibisen and Tianfu Communication reported substantial year-on-year profit growth, with increases of 30.84% and 37.46%, respectively [6] - The domestic ETC chip market leader reported a 149.33% increase in net profit for the first half of the year, showcasing strong financial performance [6] Group 4 - The market transaction volume has consistently exceeded 2 trillion, with the Shanghai Composite Index reaching a 10-year high, reflecting robust market activity [10] - Companies in the rare earth sector, such as China Minmetals, are experiencing significant performance increases, driven by new regulatory measures [10] - The government is accelerating the cultivation of new growth points in service consumption and new consumption models, indicating a shift in economic focus [10]

Summary of Key Points from Conference Call Records Company: Horizon Robotics - **Revenue Performance**: In H1 2025, Horizon Robotics reported revenue of 1.57 billion yuan, a year-on-year increase of 68%, exceeding the expected 1.43 billion yuan. Gross profit was 1.02 billion yuan, a 39% increase year-on-year, but slightly below the expected 1.04 billion yuan [1] - **Business Segmentation**: Revenue from automotive products and solutions reached 780 million yuan, up 250% year-on-year, with shipments of 1.98 million units, a 115% increase. Revenue from automotive licensing and services was 740 million yuan, a 6.9% increase year-on-year [1] - **Market Position**: Horizon Robotics is the first domestic company to achieve a shipment volume of over 10 million units in intelligent driving technology, holding market shares of 32.4% in autonomous driving computing solutions and 45.8% in ADAS front-view integrated machines, both ranking first in the market [1] - **Core Partner**: Zhongke Chuangda, which has a joint venture with Horizon Robotics, reported a non-net profit of 49 million yuan in Q2 2025, a 16-fold increase year-on-year, driven by a 136% increase in revenue from AloT business [1] Industry: Satellite Communication - **Government Initiatives**: On August 27, 2025, the Ministry of Industry and Information Technology released guidelines to promote the development of the satellite communication industry, aiming for over 10 million users of direct satellite connections by 2030 [2] - **Market Developments**: Domestic progress includes China Telecom's plan to promote over 30 direct connection models by May 2025, with annual sales expected to exceed 16 million units [2] - **Key Technologies**: Phased array and beamforming technologies are critical for the implementation of direct satellite communication [3] Industry: Medical and Pharmaceutical - **Policy Framework**: The Ministry of Commerce and Jiangsu Provincial Government issued a development plan for the biopharmaceutical industry on August 27, 2025, focusing on innovation in drugs and high-end medical devices [5] - **Market Size**: In 2024, Jiangsu is expected to approve 352 new drugs, including 13 innovative drugs, leading the nation. The biopharmaceutical cluster in Jiangsu is projected to generate revenue of 454.39 billion yuan in 2024, accounting for 15.3% of the national total [5] - **Core Companies**: Weisi Medical, specializing in non-invasive brain-machine interfaces, and Zhaoyan New Drug, which provides non-clinical research services, are highlighted as key players in the sector [5] Company: Dongtian Microelectronics - **Financial Performance**: In H1 2025, Dongtian Microelectronics reported revenue of 376 million yuan, a 42.29% increase year-on-year, with a non-net profit of approximately 49.78 million yuan, up 109.47% [6] - **Product Expansion**: The company is expanding its product offerings in optical communication and consumer electronics, including camera optical components supplied to Huawei [6] Company: Haosi Automotive Electronics - **Strategic Partnership**: Haosi Automotive Electronics has become a key partner of NVIDIA Jetson Thor, focusing on developing control systems for robotics [7] - **Market Trends**: The value of single-vehicle perception systems is increasing, with prices rising from below 1,000 yuan to 3,000-4,000 yuan per unit due to the proliferation of intelligent driving technologies [7] Company: Yunnan Energy Investment - **Renewable Energy Development**: Yunnan Rongyao New Energy is undergoing compliance checks for its integration into Yunnan Energy Investment, which will increase its renewable energy capacity by nearly 50% [8] - **Financial Projections**: Assuming an annual power generation of 1.2 billion kWh and an electricity price of 0.35 yuan per kWh, the projected annual revenue could reach approximately 420 million yuan, with net profits estimated between 150 million to 200 million yuan [8] Company: Zhongxin Group - **Revenue Growth**: In Q2 2025, Zhongxin Group reported revenue of 1.246 billion yuan, a 161% increase year-on-year, driven by land development and industrial investment [9] - **Operational Metrics**: The company has developed a total area of 3 million square meters in industrial parks, with an occupancy rate of 81% [9] Company: Broadcom Integration - **AI Chip Demand**: Broadcom Integration is benefiting from the growing demand for AI chips in smart terminals, with a focus on Wi-Fi MCU and various AI-integrated chips for applications in AI glasses and toys [10]

Market Overview - The Shanghai Composite Index fell by 1.76% on August 27, with only one industry, communication, showing an increase of 1.66%. The beauty care and real estate sectors experienced the largest declines, down 3.86% and 3.51% respectively. The pharmaceutical and biotechnology sector also saw a decrease of 2.73% [1]. Capital Flow Analysis - The main capital outflow from both markets totaled 129.75 billion yuan, with all sectors under the Shenwan classification experiencing net outflows. The computer industry led with a net outflow of 16.31 billion yuan, followed by the pharmaceutical and biotechnology sector with a net outflow of 12.33 billion yuan. Other sectors with significant outflows included electronics, automotive, and machinery equipment [1]. Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector had 474 stocks, with 36 gaining and 438 losing value. Five stocks hit the daily limit up, while one stock hit the limit down. The sector saw a net outflow of 12.33 billion yuan, with 114 stocks experiencing net inflows, and 28 stocks seeing outflows exceeding 100 million yuan [2]. Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jimin Health: +9.97% with a net inflow of 118.04 million yuan - Nanxin Pharmaceutical: +20.00% with a net inflow of 109.05 million yuan - BGI Genomics: +0.09% with a net inflow of 106.94 million yuan [2]. Major Outflows in Pharmaceutical Sector - The stocks with the largest net outflows included: - Hengrui Medicine: -3.45% with a net outflow of 901.64 million yuan - WuXi AppTec: -1.45% with a net outflow of 482.18 million yuan - Guangsheng Tang: -10.32% with a net outflow of 378.57 million yuan [3].

Market Overview - The medical device sector experienced a decline of 1.98% on August 27, with Hanbang Technology leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Top Gainers in Medical Device Sector - Aomei Medical (002950) saw a closing price of 10.74, with a significant increase of 10.04% and a trading volume of 436,600 shares, totaling a transaction value of 467 million yuan [1] - Jimin Health (603222) closed at 10.04, up 9.97%, with a trading volume of 1,165,700 shares, amounting to 1.118 billion yuan [1] - Meihai Medical (301363) closed at 25.58, increasing by 4.45% with a trading volume of 463,000 shares, totaling 1.22 billion yuan [1] Top Decliners in Medical Device Sector - Hanbang Technology (688755) closed at 47.70, down 11.91%, with a trading volume of 62,100 shares, resulting in a transaction value of 305 million yuan [2] - Rejing Bio (688068) closed at 211.99, decreasing by 10.47%, with a trading volume of 44,900 shares [2] - Wuzhou Medical (301234) closed at 42.83, down 8.13%, with a trading volume of 54,400 shares, totaling 239 million yuan [2] Capital Flow Analysis - The medical device sector saw a net outflow of 2.272 billion yuan from institutional investors, while retail investors experienced a net inflow of 1.684 billion yuan [2] - Jimin Health (603222) had a net inflow of 105 million yuan from institutional investors, but a net outflow of 30.37 million yuan from retail investors [3] - Aomei Medical (002950) recorded a net inflow of 83.90 million yuan from institutional investors, with a net outflow of 43.40 million yuan from retail investors [3]

Group 1: Company Performance - Nengke Technology reported a net profit growth of 18.75% year-on-year in its mid-year report, focusing on smart manufacturing and developing a comprehensive product system that includes AI applications across various industrial scenarios [2][3] - Jianye Technology achieved a net profit growth of 51.12% year-on-year, supplying high-speed optical modules to Microsoft, with 800G products in small batch delivery [2] - Lianhua Technology, a leader in custom production of pesticide intermediates, reported a staggering net profit growth of 1481.94% year-on-year [2] - Xianggang Technology, a provider of integrated solutions in printing and packaging, saw a net profit increase of 432.14% year-on-year [2] - Dongpeng Holdings, primarily engaged in ceramics and sanitary ware, reported a net profit growth of 3.85% year-on-year, significantly up from the first quarter [2] - Aonong Bio reported a net profit of 361 million, marking a turnaround from losses [2] - Qiming Information, under FAW Group, reported a net profit growth of 2568.5% year-on-year, focusing on digital operations and smart marketing [2] Group 2: Industry Trends - The State Council issued an opinion on the implementation of the "Artificial Intelligence +" initiative, aiming for over 70% penetration of new intelligent terminals and applications by 2027 [2][4] - The demand for liquid cooling solutions in data centers is increasing, with companies like Huangma Technology focusing on organic silicon modified polyether as a supplier for immersion cooling liquids [4] - The agricultural sector is seeing significant developments, with Aonong Co. reporting a net profit of 361 million, indicating a recovery in the agricultural products market [5] Group 3: Strategic Partnerships and Collaborations - Ge'ern Automotive has entered a strategic partnership with NVIDIA to develop control systems for robots, covering the entire range of NVIDIA's Jetson series [3] - Magmi Technology has formed a partnership with NVIDIA to become a designated supplier of data center components, actively participating in the design and construction of NVIDIA's Blackwell architecture [4]

Group 1 - The core viewpoint of the news is that Jimin Health has experienced a significant stock price increase, reaching a limit up of 9.97% on August 27, with a trading price of 10.04 yuan per share and a total market capitalization of 5.272 billion yuan [1] - Jimin Health Management Co., Ltd. is primarily engaged in medical health services, medical devices, and chemical pharmaceuticals, with over 30 years of business history and leading positions in safety injection and puncture devices both domestically and internationally [1] - The company has established production bases in Zhejiang, Shanghai, and Spain, and owns six wholly-owned or controlled subsidiaries, along with two general hospitals actively expanding into the health industry [1] Group 2 - As of June 30, Jimin Health had 28,100 shareholders, with an average of 18,700 circulating shares per shareholder [2] - For the first half of 2025, Jimin Health reported operating revenue of 366 million yuan, a year-on-year decrease of 21.30%, and a net profit attributable to shareholders of -52.6959 million yuan, a year-on-year decrease of 307.10% [2]